Coegin Pharma AB

Basal Cell Neoplasm Drug Pipeline Expands with 22+ Companies Developing Novel Therapies

- Over 22 pharmaceutical companies are actively developing 25+ pipeline drugs for basal cell neoplasms, the most common type of skin cancer characterized by slow growth and low metastatic potential. - Recent clinical milestones include Senhwa Biosciences completing Phase I trials for Silmitasertib with positive survival outcomes, and multiple companies reporting positive Phase II results for their respective candidates. - Leading late-stage candidates include Sol-Gel Technologies' Patidegib, a first-in-class topical hedgehog pathway inhibitor targeting Gorlin Syndrome and basal cell carcinomas. - The pipeline features diverse mechanisms of action including SMO protein inhibitors, tyrosine kinase inhibitors, and casein kinase II inhibitors, addressing the growing demand driven by rising UV exposure and aging populations.